BlinkLab (ASX:BB1) added Drexel University as a clinical site for its pivotal US regulatory trial for its BlinkLab Dx 1 autism diagnostic test, according to a Thursday Australian bourse filing.
Drexel University became the ninth institution to participate in the FDA 510(k) registrational trial across the US. The study will enroll around 528 children, between the ages of 2 and 11 years.
Its shares fell 4% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.